United Therapeutics Corporation (UTHR)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 1,697,200 | 1,553,900 | 1,355,700 | 1,251,500 | 1,207,700 | 1,107,700 | 1,067,300 | 1,163,500 | 961,200 | 966,800 | 795,200 | 813,300 | 894,800 | 908,500 | 942,200 | 832,300 | 738,700 | 670,200 | 685,400 | 875,200 |
| Short-term investments | US$ in thousands | 1,569,800 | 1,772,600 | 1,615,800 | 1,456,300 | 1,786,400 | 3,828,600 | 3,635,300 | 1,699,900 | 1,877,500 | 1,648,800 | 1,460,000 | 1,454,400 | 1,035,900 | 1,091,900 | 1,025,300 | 899,000 | 1,096,300 | 910,300 | 875,300 | 669,300 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 738,100 | 873,400 | 832,300 | 860,600 | 804,400 | 744,100 | 370,300 | 324,600 | 343,200 | 315,900 | 331,500 | 292,600 | 305,400 | 320,000 | 311,400 | 302,400 | 323,300 | 258,900 | 255,000 | 207,300 |
| Quick ratio | 4.43 | 3.81 | 3.57 | 3.15 | 3.72 | 6.63 | 12.70 | 8.82 | 8.27 | 8.28 | 6.80 | 7.75 | 6.32 | 6.25 | 6.32 | 5.73 | 5.68 | 6.10 | 6.12 | 7.45 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($1,697,200K
+ $1,569,800K
+ $—K)
÷ $738,100K
= 4.43
The quick ratio of United Therapeutics Corporation has shown fluctuation over the period from March 31, 2020, to December 31, 2024. The quick ratio, which measures the company's ability to meet its short-term obligations using its most liquid assets, has ranged from a high of 12.70 on June 30, 2023, to a low of 3.15 on March 31, 2024.
The quick ratio indicates the company's ability to cover its current liabilities with its quick assets, such as cash, marketable securities, and accounts receivable. A higher quick ratio is generally considered favorable as it suggests that the company possesses more than enough liquid assets to cover its short-term obligations.
United Therapeutics Corporation's quick ratio has generally remained above 1.0, indicating that the company has a sufficient level of quick assets to cover its current liabilities. The ratio peaked at 12.70 on June 30, 2023, suggesting a strong ability to meet short-term obligations, while the lowest point of 3.15 on March 31, 2024, may indicate a temporary strain on liquidity.
Overall, the trend in the quick ratio suggests that United Therapeutics Corporation has maintained a relatively stable ability to meet its short-term obligations with its readily available liquid assets over the analyzed period.
Peer comparison
Dec 31, 2024